TY - JOUR
T1 - Hereditary ovarian carcinoma
T2 - Heterogeneity, molecular genetics, pathology, and management
AU - Lynch, Henry T.
AU - Casey, Murray Joseph
AU - Snyder, Carrie L.
AU - Bewtra, Chhanda
AU - Lynch, Jane F.
AU - Butts, Matthew
AU - Godwin, Andrew K.
N1 - Funding Information:
This paper was supported by revenue from Nebraska cigarette taxes awarded to Creighton University by the Nebraska Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the State of Nebraska or the Nebraska Department of Health and Human Services. Support was also given by the National Institutes of Health through grant #1U01 CA 86389.
Funding Information:
Dr. Henry Lynch's work is partially funded through the Charles F. and Mary C. Heider Chair in Cancer Research, which he holds at Creighton University.
Funding Information:
Support was provided to Dr. Andrew K. Godwin by the Ovarian Cancer Research Fund and the Ovarian Cancer SPORE at Fox Chase Cancer Center (P50 CA083638).
PY - 2009/4
Y1 - 2009/4
N2 - Hereditary ovarian cancer accounts for at least 5% of the estimated 22,000 new cases of this disease during 2009. During this same time, over 15,000 will die from malignancy ascribed to ovarian origin. The bulk of these hereditary cases fits the hereditary breast-ovarian cancer syndrome, while virtually all of the remainder will be consonant with the Lynch syndrome, disorders which are autosomal dominantly inherited. Advances in molecular genetics have led to the identification of BRCA1 and BRCA2 gene mutations which predispose to the hereditary breast-ovarian cancer syndrome, and mutations in mismatch repair genes, the most common of which are MSH2 and MLH1, which predispose to Lynch syndrome. These discoveries enable relatively certain diagnosis, limited only by their variable penetrance, so that identification of mutation carriers through a comprehensive cancer family history might be possible. This paper reviews the subject of hereditary ovarian cancer, with particular attention to its molecular genetic basis, its pathology, and its phenotypic/genotypic heterogeneity.
AB - Hereditary ovarian cancer accounts for at least 5% of the estimated 22,000 new cases of this disease during 2009. During this same time, over 15,000 will die from malignancy ascribed to ovarian origin. The bulk of these hereditary cases fits the hereditary breast-ovarian cancer syndrome, while virtually all of the remainder will be consonant with the Lynch syndrome, disorders which are autosomal dominantly inherited. Advances in molecular genetics have led to the identification of BRCA1 and BRCA2 gene mutations which predispose to the hereditary breast-ovarian cancer syndrome, and mutations in mismatch repair genes, the most common of which are MSH2 and MLH1, which predispose to Lynch syndrome. These discoveries enable relatively certain diagnosis, limited only by their variable penetrance, so that identification of mutation carriers through a comprehensive cancer family history might be possible. This paper reviews the subject of hereditary ovarian cancer, with particular attention to its molecular genetic basis, its pathology, and its phenotypic/genotypic heterogeneity.
UR - http://www.scopus.com/inward/record.url?scp=63549096634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=63549096634&partnerID=8YFLogxK
U2 - 10.1016/j.molonc.2009.02.004
DO - 10.1016/j.molonc.2009.02.004
M3 - Review article
C2 - 19383374
AN - SCOPUS:63549096634
VL - 3
SP - 97
EP - 137
JO - Molecular Oncology
JF - Molecular Oncology
SN - 1574-7891
IS - 2
ER -